chemieunternehmen.com

Eternygen today announced the first closing of its Series A2 funding round led by new anchor investor Evotec SE and additional funding from venture capital firms Epidarex Capital, IBB Ventures and a number of family offices. The new investment amounting to € 5 m will be used to drive Eternygen’s development of novel treatments for non-alcoholic steatohepatitis („NASH“) to the next milestone, i.e. the selection of a preclinical development candidate, the initiation of IND enabling studies as well as growing clinical capabilities within the team. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/eternygen-announces-the-first-closing-of-its-series-a2-funding-round-5988

Topas Therapeutics GmbH, a Hamburg, Germany-based private platform company leveraging the natural immune tolerance induction capabilities of the liver, today announced the successful closing of a € 22 m (~US$ 26 m) Series B financing round. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/topas-therapeutics-raises-eur-22-m-us-26-m-in-series-b-financing-and-appoints-klaus-martin-phd-as-chief-executive-officer-5987

Evotec SE today announced that its Seattle-based subsidiary, Just – Evotec Biologics, Inc., received a grant from the Bill & Melinda Gates Foundation (Seattle, WA) as part of the COVID-19 Therapeutics Accelerator to enable the development and production of monoclonal antibody (“mAb”) candidates for the prevention of severe COVID-19 in vulnerable populations in low and middle income countries. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/just—evotec-biologics-receives-grant-to-enable-an-antibody-product-for-the-prevention-of-covid-19-5984

Evotec SE today announced that it resolved a capital increase from its authorised capital without pre-emptive rights against cash. Evotec will issue a total of 11,478,315 new shares to Mubadala Investment Company and Novo Holdings A/S, increasing Evotec’s cash reserves by € 250 million in total.     Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/mubadala-investment-company-and-novo-holdings-as-invest-eur-250-m-in-evotec-se-5983

Evotec SE announced today that the Company has received a US$ 6 m payment from Bristol Myers Squibb Company following the decision to expand the portfolio by another drug discovery project. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-achieves-milestone-in-neurodegeneration-collaboration-with-bristol-myers-squibb-5978